Compass Therapeutics, Inc. — Director's Dealing 2022

Nov 22, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (CMPX)
CIK: 0001738021
Period of Report: 2022-11-18

Reporting Person: Bisker-Leib Vered (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-18	Common Stock	S	6226	$4.40	Disposed	1107175	Direct
2022-11-21	Common Stock	S	16035	$4.34	Disposed	1084914	Direct

Footnotes

F1: The sales reported on this Form represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are included in the Reporting Person's award agreement which allows the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction.

F2: The price reported in Column 4 is the weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $4.31 to $4.49 per share on November 18, 2022 and $4.30 to $4.44 on November 21, 2022. The reporting person hereby undertakes to provide, upon request, to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, full information regarding the number of shares purchased and prices within the range set forth above.